Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

NCT06672536 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

nAMD

Interventions

DRUG: SCT520FF
DRUG: SCT520FF
DRUG: SCT520FF
DRUG: EYLEA 2 MG

Sponsor

Sinocelltech Ltd.

Collaborators

[object Object]